Kodiak Sciences reported pivotal Phase 3 DAYBREAK results for its retinal drug candidates, sending shares sharply higher on September 28. The detailed supplied report says Zenkuda met the study's primary vision endpoint against aflibercept, with a reported p-value of 0.0007. Fifty-four percent of patients receiving Zenkuda reached six-month dosing at year one under the study's retreatment rules.
Durability is the central commercial question. Wet age-related macular degeneration requires repeated treatment, so reducing the number of injections while preserving vision and retinal disease control could matter to patients, physicians and clinic capacity. The study's comparator was aflibercept, used in Regeneron's Eylea franchise. The supplied reports also describe the second candidate, tabirafusp alfa tedromer, as meeting its vision endpoint, although individual sources differ in the level of trial detail they provide.
This should not be reduced to the size of the one-day stock rally. The source says Kodiak remains precommercial and plans a Zenkuda application in the fourth quarter of 2026, drawing on five positive Phase 3 studies across multiple retinal indications. Regulatory review and eventual labeling will determine how much of the trial's apparent dosing advantage can be marketed. The supplied report also states a zero percent intraocular-inflammation rate in the reported Zenkuda arm and a 0.5% cataract rate, compared with 0.9% for aflibercept; full study tables remain important for judging the overall safety profile.
Competition is not static. Established retinal treatments already offer extended intervals for some patients, and real-world adherence and physician confidence will influence uptake. Kodiak will also need launch financing and execution if approval is granted. The large share-price response raises the cost of later disappointment.
What investors should watch: the full DAYBREAK dataset, subgroup response and safety, the planned fourth-quarter filing, FDA feedback, cash runway, launch preparation and forthcoming KSI-101 Phase 3 results.
BTI’s bottom line: the trial provides a meaningful clinical catalyst, particularly the six-month dosing result, but the transition from pivotal efficacy to an approved and competitive product is still the investment test.